Trident Texofab pockets ₹1.59 cr as 9.11 lakh warrants lapse
Warrants from December 2024 preferential issue went unexercised. The upfront cash equals about 2.9% of market cap, a material one-time gain for the nano-cap.
What's new
- Trident Texofab forfeited 9,11,479 fully convertible warrants from its December 2024 preferential issue.
- The upfront amount of ₹1.59 crore is retained; no equity shares were issued.
- The cash gain is about 2.9% of market cap, material for a ₹59 crore nano-cap.
Why this matters
For a company with trailing PAT down 494% and a P/E of 83.3, a one-time cash injection of ₹1.59 crore will meaningfully lift book value and earnings this quarter. But it's non-recurring — the operating business remains under pressure.
What we're watching
- Whether the company uses the cash to pare debt (D/E 0.56) or fund working capital.
- Next quarterly results for signs of core business recovery.
- Any further fund-raise plans after this warrant lapse.
The full read
Trident Texofab just pocketed ₹1.59 crore in free cash. The money comes from 9,11,479 fully convertible warrants issued in December 2024 that holders chose not to exercise. The ₹70-a-share warrants required only 25% upfront, yet not a single warrant was converted by the June 22 deadline. All 9.11 lakh lapsed. For a ₹59 crore nano-cap with trailing PAT down 494% and a P/E of 83.3, that ₹1.59 crore is a material windfall, roughly 2.9% of market cap. The equity base stays unchanged, so book value and earnings get a one-time lift. But the operating business, with revenue down 12.1% and debt at 0.56 times equity, remains under stress. This is a pleasant surprise, not a turnaround.
Questions answered
- What exactly happened with Trident Texofab's warrants?
- The company had issued 9.11 lakh fully convertible warrants at ₹70 each in December 2024. Holders paid 25% upfront (₹17.50 per warrant) but failed to exercise them by the June 22, 2026 deadline. The warrants are now forfeited.
- How much cash did Trident Texofab retain?
- The upfront payment totaled ₹1.59 crore, which the company keeps. This is about 2.9% of its current market cap of ₹59 crore.
- Did the forfeiture change the company's share count?
- No. Paid-up capital remains unchanged because no equity shares were issued against these warrants.
- Is this a one-time gain or something recurring?
- It's a non-recurring gain. The cash will boost earnings and book value in the quarter it's recognized, but it does not reflect an improvement in the underlying textile business, which has seen revenue fall 12.1% and PAT slump 494% on a trailing basis.
- How does this compare to the company's earnings?
- Trailing PAT is deeply negative, so even a small absolute gain of ₹1.59 crore is significant. However, it's a one-off and does not change the structural challenges.